Hyaluronic Acid Nanoparticle-Encapsulated MicroRNA-125B Repolarizes Tumor-Associated Macrophages in Pancreatic Cancer

Parayath, Neha N.; Hong, Brian V.; Mackenzie, Gerardo G.; Amiji, Mansoor M.

doi:10.2217/nnm-2021-0080

Cited by 21 publications

(19 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatments produced a potent antitumor immune memory that prevented tumor reformation after a secondary challenge, providing a potential strategy for preventing tumor recurrence. Injection of microRNA-125b encapsulated in a hyaluronic acid nanoparticle reprogrammed tumor-associated macrophages from protumor to antitumor phenotypes 236 …”

Section: Late Diagnosismentioning

confidence: 99%

Advancements in Preclinical Models of Pancreatic Cancer

Salu,

Reindl

2024

Pancreas

View full text Add to dashboard Cite

Pancreatic cancer remains one of the deadliest of all cancer types with a 5-year overall survival rate of just 12%. Preclinical models available for understanding the disease pathophysiology have evolved significantly in recent years. Traditionally, commercially available 2-dimensional cell lines were developed to investigate mechanisms underlying tumorigenesis, metastasis, and drug resistance. However, these cells grow as monolayer cultures that lack heterogeneity and do not effectively represent tumor biology. Developing patient-derived xenografts and genetically engineered mouse models led to increased cellular heterogeneity, molecular diversity, and tissues that histologically represent the original patient tumors. However, these models are relatively expensive and very timing consuming. More recently, the advancement of fast and inexpensive in vitro models that better mimic disease conditions in vivo are on the rise. Three-dimensional cultures like organoids and spheroids have gained popularity and are considered to recapitulate complex disease characteristics. In addition, computational genomics, transcriptomics, and metabolomic models are being developed to simulate pancreatic cancer progression and predict better treatment strategies. Herein, we review the challenges associated with pancreatic cancer research and available analytical models. We suggest that an integrated approach toward using these models may allow for developing new strategies for pancreatic cancer precision medicine.

show abstract

Section: Late Diagnosismentioning

confidence: 99%

Advancements in Preclinical Models of Pancreatic Cancer

Salu,

Reindl

2024

Pancreas

View full text Add to dashboard Cite

show abstract

“…Hyaluronic acid nanoparticle-encapsulated miRNA-125b reprogrammed TAMs to an antitumor phenotype in PDAC[ 143 ]. M2-TAM-targeting nanomicelles were created to simultaneously deliver PI3K-γ inhibitor NVP-BEZ 235 and CSF-1R-siRNA, leading to specific TAM reprogramming and antitumor immune response activation[ 144 ].…”

Section: Tams and Targeted Therapies Of Digestive System Malignant Tu...mentioning

confidence: 99%

Role of tumor-associated macrophages in common digestive system malignant tumors

Shen¹,

Chen²,

Li³

et al. 2023

World J Gastrointest Oncol

View full text Add to dashboard Cite

Many digestive system malignant tumors are characterized by high incidence and mortality rate. Increasing evidence has revealed that the tumor microenvironment (TME) is involved in cancer initiation and tumor progression. Tumor-associated macrophages (TAMs) are a predominant constituent of the TME, and participate in the regulation of various biological behaviors and influence the prognosis of digestive system cancer. TAMs can be mainly classified into the antitumor M1 phenotype and protumor M2 phenotype. The latter especially are crucial drivers of tumor invasion, growth, angiogenesis, metastasis, immunosuppression, and resistance to therapy. TAMs are of importance in the occurrence, development, diagnosis, prognosis, and treatment of common digestive system malignant tumors. In this review, we summarize the role of TAMs in common digestive system malignant tumors, including esophageal, gastric, colorectal, pancreatic and liver cancers. How TAMs promote the development of tumors, and how they act as potential therapeutic targets and their clinical applications are also described.

show abstract

“…The final results showed that this dual delivery system polarized inhibitory TAM, recruited CTLs, and down-regulated Treg, thus eliciting a potent antitumor immune response. In another study, Parayath et al constructed M2 peptide-modified polymer NPs for TAM-targeted miR-125b delivery [ 112 ]. The results showed that intraperitoneal administration of M2-targeted NPs showed preferential accumulation at the tumor site, and the ratio of M1-to-M2-TAM increased more than fourfold.…”

Section: Well-designed Nanosystems For Different Pdac Therapeuticsmentioning

confidence: 99%

Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma

Yang

et al. 2023

Molecules

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with an extremely poor prognosis and low survival rate. Due to its inconspicuous symptoms, PDAC is difficult to diagnose early. Most patients are diagnosed in the middle and late stages, losing the opportunity for surgery. Chemotherapy is the main treatment in clinical practice and improves the survival of patients to some extent. However, the improved prognosis is associated with higher side effects, and the overall prognosis is far from satisfactory. In addition to resistance to chemotherapy, PDAC is significantly resistant to targeted therapy and immunotherapy. The failure of multiple treatment modalities indicates great dilemmas in treating PDAC, including high molecular heterogeneity, high drug resistance, an immunosuppressive microenvironment, and a dense matrix. Nanomedicine shows great potential to overcome the therapeutic barriers of PDAC. Through the careful design and rational modification of nanomaterials, multifunctional intelligent nanosystems can be obtained. These nanosystems can adapt to the environment’s needs and compensate for conventional treatments’ shortcomings. This review is focused on recent advances in the use of well-designed nanosystems in different therapeutic modalities to overcome the PDAC treatment dilemma, including a variety of novel therapeutic modalities. Finally, these nanosystems’ bottlenecks in treating PDAC and the prospect of future clinical translation are briefly discussed.

show abstract

Hyaluronic Acid Nanoparticle-Encapsulated MicroRNA-125B Repolarizes Tumor-Associated Macrophages in Pancreatic Cancer

Cited by 21 publications

References 25 publications

Advancements in Preclinical Models of Pancreatic Cancer

Advancements in Preclinical Models of Pancreatic Cancer

Role of tumor-associated macrophages in common digestive system malignant tumors

Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma

Contact Info

Product

Resources

About